An open single center single arm clinical study of infusion of anti-CD19 CAR-T and anti-CD22 CAR-T therapy after autologous hematopoietic stem cell transplantation (auto-HSCT) for relapsed, refractory and high-risk B cell lymphoma

Trial Profile

An open single center single arm clinical study of infusion of anti-CD19 CAR-T and anti-CD22 CAR-T therapy after autologous hematopoietic stem cell transplantation (auto-HSCT) for relapsed, refractory and high-risk B cell lymphoma

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs CAR-T cell therapies (Primary)
  • Indications Acute lymphoblastic leukaemia; B cell lymphoma; B-cell leukaemia; Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top